Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer. - Test2 - elhamkhani - TriplyDB

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.

http://www.wikidata.org/entity/Q39357705

about

Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma GSK3β-dependent phosphorylation alters DNA binding, transactivity and half-life of the transcription factor USF2.A screen for transcription factor targets of glycogen synthase kinase-3 highlights an inverse correlation of NFκB and androgen receptor signaling in prostate cancer Insights into the interactions between maleimide derivates and GSK3β combining molecular docking and QSAR Discrete functions of GSK3α and GSK3β isoforms in prostate tumor growth and micrometastasis.KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer.Glycogen synthase kinase-3: a potential preventive target for prostate cancer management Serpine2, a potential novel target for combating melanoma metastasis Hyperinsulinemia enhances interleukin-17-induced inflammation to promote prostate cancer development in obese mice through inhibiting glycogen synthase kinase 3-mediated phosphorylation and degradation of interleukin-17 receptor.Activation of the Wnt pathway through AR79, a GSK3β inhibitor, promotes prostate cancer growth in soft tissue and bone.Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases 6BIO Enhances Oligonucleotide Activity in Cells: A Potential Combinatorial Anti-androgen Receptor Therapy in Prostate Cancer Cells.Does Wnt/β-catenin pathway contribute to the stability of DNMT1 expression in urological cancer cell lines?Pro-oxidant treatment of human prostate carcinoma (DU145) induces autoschizis cell death: autophagosomes build up out of injured endomembranes and mitochondria.Suppression of Akt1-β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis.Unraveling the role of Arg4 and Arg6 in the auto-inhibition mechanism of GSK3β from molecular dynamics simulation.Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells.Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancer

P2860

Q26739711-428A07C0-25EA-416C-986F-2E34B666F5A1 Q33569998-59654460-453E-4F70-BE5D-EC13D000A5C7 Q34216085-89C68D6A-37BB-4695-85F5-6E2624CD4406 Q34483490-A8173379-16A3-40C4-BC5D-12CA7368B93D Q35204391-F44939E1-5EF6-47F7-971B-084E87267AA8 Q35742439-2DCC8514-3349-4650-B4B8-3ABBF4D05F47 Q35856215-26C33827-6B19-4D2F-8BB0-9FE71203C862 Q35980822-395CD186-9F1D-45D9-BA4E-7AF84A4743A9 Q36580561-A11AC593-0CEA-4A23-B861-0C23C948D6ED Q36964051-717F485A-45BF-465C-9937-E1BE2A8CFF16 Q37046424-93695202-0611-4FA2-B8C7-7DDADFFFE819 Q37407566-A19C0C54-F4EC-4D1E-9785-71E76919611F Q37718461-A632896B-5A65-4ADB-9DF7-05201553A02F Q38272835-A83917D3-C9F3-4406-A311-B097E5BD725C Q38719143-D6EDD5A5-0E24-4914-A27D-33E9744D09DA Q38944664-689AB830-C14A-4636-8044-E209AF09A4FA Q38982040-D96B4A39-3073-4302-8EA9-ABC7698295C1 Q50590583-1628B0AD-9E12-4CEB-A4CC-FED8B8F2F96A Q54383410-E35DA1B3-130E-4EF9-AFD3-8F198B859BCF Q54936181-3A217C01-52D4-438C-8215-987D6947E25C Q58572626-AC579F07-5A04-4171-8FE8-A0DC98DAF715

P2860

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.

http://www.wikidata.org/entity/Q39357705

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.

@en

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.

@nl

type

label

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.

@en

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.

@nl

prefLabel

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.

@en

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.

@nl

P1433

Q39357705-D62B7928-23E4-4D64-838D-126093961DA4

P1476

Q39357705-6E56830D-87A0-4FBE-B3B1-1E78754072FE

P2093

Q39357705-53E67A3B-21CD-453D-A3B7-820AAFE77356

Q39357705-64DFA931-363F-4E95-A5BA-12FFAC5594BA

Q39357705-6C33D566-BAEA-4BE9-9296-DEDD1471A452

Q39357705-A756F594-3438-475F-BAB0-95EE5843D164

Q39357705-AE24BF06-28A6-4FAC-B509-F472640D1617

Q39357705-B3BC6384-9EDB-4839-A9CB-98BE91CB5F11

P2860

Q39357705-0722461B-235A-4E38-9D49-AD6526EDEFEC

Q39357705-099E56D8-5768-4FB0-95EE-6988B34F105D

Q39357705-0A201045-8F20-4A8A-BAF4-F835F7311E61

Q39357705-0C6FC320-00AD-476A-BCC3-811BF04F4D7E

Q39357705-129B42B1-DC49-4351-9019-3A5AC9FB7426

Q39357705-12CF4E04-C07E-47D7-AAB8-9B84BF790CD7

Q39357705-1503712C-D310-4E60-A698-DD58586367CB

Q39357705-1561D80D-D775-4BA2-A51A-A8312BE3BBBA

Q39357705-1B31B9C3-85BB-43A2-A4E5-11327E2EE112

Q39357705-1D3A4F9D-5083-494C-8AE1-C1432F00B827

P304

Q39357705-1EBD3E76-6BC0-4235-89BB-ECEB03FF3EDA

P31

Q39357705-10ABF816-8C58-4995-AB40-D16988CDAFD6

P356

Q39357705-5B6D6457-412B-48C1-93E2-4E5454E03EC4

P433

Q39357705-C0E33344-98BF-4DF3-9685-5E645EA5129A

P478

Q39357705-5B18AEC4-AB8E-4A84-B9D2-ED962D61B7CA

P50

Q39357705-53B38302-9F5D-4C34-AE21-123060D1006A

Q39357705-859C25AC-46A0-497C-B2FB-BB6594915C03

Q39357705-EE9B92D8-B475-46A4-A1FD-13DA2E0B2D93

P577

Q39357705-D8FE44AA-D1E9-4FE6-9DE1-4DB6A07769C0

P5875

Q39357705-B103258B-7860-457F-9C44-8FEB990C223C

P698

Q39357705-9F299F1B-2265-4B3C-A0D1-79773BED0904

P356

P1433

International Journal of Cancer

P1476

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer

@en

P2093

Irantzu Gorrono-Etxebarria

http://www.w3.org/2001/XMLSchema#string

Jonathan Waxman

http://www.w3.org/2001/XMLSchema#string

Marjorie M Walker

http://www.w3.org/2001/XMLSchema#string

Pinar Uysal-Onganer

http://www.w3.org/2001/XMLSchema#string

R Siobhan Darrington

http://www.w3.org/2001/XMLSchema#string

Yoshiaki Kawano

http://www.w3.org/2001/XMLSchema#string

P2860

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells

Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

GSK-3: tricks of the trade for a multi-tasking kinase

Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor

The selectivity of protein kinase inhibitors: a further update

Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells

Integrative genomic profiling of human prostate cancer

P304

E872-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.27620

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

Víctor M Campa

Nora Bengoa-Vergniory

P577

2012-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224855455

http://www.w3.org/2001/XMLSchema#string

P698

22539113

http://www.w3.org/2001/XMLSchema#string